Omnio’s mission is to help people with hard-to-heal diabetic foot ulcers regain mobility and avoid amputation. The lead drug candidate is a recombinant form of plasminogen, a protein with pro-inflammatory and immunoregulatory properties.

The GMP-adapted manufacturing process is currently being finalized, with preclinical regulatory studies planned for later this summer. Phase IIa clinical trials are scheduled to begin in mid-2026.

Plans to expand the workforce

With fresh funding, the company plans to expand its workforce and strengthen the regulatory and manufacturing teams during 2025, it states.

“We’ll continue to grow our R&D capacity as we develop additional therapies beyond diabetic foot ulcers over the next two to three years. R&D positions will likely be based in Umeå, while locations for other roles are yet to be determined,” says Velasquez.